盐酸拓扑替康治疗顺铂耐药复发卵巢癌的临床研究  

Clinical efficacy of topotecan in the treatment of platinum-resistant ovarian cancer

作　　者：杨谨[1] 赵西侠 曾令霞[3] 李蓉[1] 

机构地区：[1]西安交通大学第一医院肿瘤内科,陕西西安710061 [2]陕西省肿瘤医院妇瘤科,陕西西安710061 [3]西安交通大学医学院公共卫生系统计教研室

出　　处：《现代肿瘤医学》2006年第8期998-1000,共3页Journal of Modern Oncology

摘　　要：目的：评价盐酸拓扑替康治疗一线顺铂耐药复发卵巢癌的近期和远期疗效及安全性。方法：对一线含顺铂方案化疗耐药复发卵巢癌患者采用盐酸拓扑替康1．25mg／m^2静滴（1-5）d，每21d重复。治疗每2周期后评价疗效，CR或PR病例继续化疗直至疾病进展或毒性不能耐受。结果：共入组患者52例，可评价临床疗效49例，可评价血清CA12-5疗效48例，可评价毒性52例。临床和CA12-5总有效率分别为22．5％和29．2％，中位缓解期为6月，中位无疾病进展生存时间和总生存时间分别为10月和16月。主要毒副作用为中性粒细胞减少和白细胞减少，两者Ⅲ-Ⅳ度毒性分别为44.2％和53.8％。非血液学毒性轻微。结论：盐酸拓扑替康单药治疗一线含顺铂方案化疗耐药复发卵巢癌疗效肯定，耐受性良好。Objective：To evaluate the short and , long-term efficacy and safety of topotecan （TPT） in the treat-ment of platinum-resistant ovarian carcinoma . Methods： All 52 patients had received platinum -based regimens previously and relapse within 6 months. Patients received TPT（ 1.25mg/m^2 ） as a 30 minute infusion daily for 5 days every 21 days. The efficacy was evaluated after 2 cycles of chemotherapy . Patients with CR or PR received further chemotherapy until progession or serious toxicity. Results ：A total of 52 patients entered into the study, 49 were assessable for clinical response and 48 for serological CA-125 response. All patients were assessable for toxicity. The response rates were 22.5% in clinical evaluation and 29.2% by CA-125 level. Median duration of response was 6 （2-13） months, median progressionfree interval was 10 months and median overall survival was 16 months. Grade 3-4 leukopenia and neutropenia occurred in 44.2% and 53.8% of the patients . Nonhematological toxicities were mild. There was no drug-related death. Conclusion： TPT is effective and well-tolerated in the treatment of plati-num-resistant ovarian carcinoma.

关 键 词：盐酸拓扑替康 卵巢癌 化疗 

分 类 号：R737.31[医药卫生—肿瘤]